GPER1 and metabolic dysfunction-associated steatotic liver disease: In conclusion, the novelty of our results suggests that GPER1 prevents the progression of NAFLD/NASH through activation of the cAMP/PKA-dependent AMPK signaling pathway, uncovering GPER1 might be a promising therapeutic target for NAFLD/NASH.